New insider activity at Benitec Biopharma ( (BNTC) ) has taken place on March 29, 2025.
Director Suvretta Capital Management, LLC has made a significant investment in Benitec Biopharma by purchasing 900,000 shares of the company’s stock. This transaction is valued at a substantial $11,700,000, indicating strong confidence in the company’s potential.
Recent Updates on BNTC stock
Benitec Biopharma has recently announced the pricing of its underwritten and registered direct offerings, expected to raise approximately $30 million to support its product development programs. The stock has seen positive momentum due to promising interim results from its BB-301 Phase 1b/2a study, which demonstrated significant improvements in swallowing function for subjects with Oculopharyngeal Muscular Dystrophy (OPMD). These results, presented at the 2025 Muscular Dystrophy Association Conference, have reinforced the company’s position in the gene therapy market and contributed to a positive outlook on the stock. Additionally, the appointment of David Friedman from Suvretta Capital to the board of directors is under discussion, following the investment from Suvretta Capital. Overall, the developments have bolstered confidence in Benitec Biopharma’s future prospects.
More about Benitec Biopharma
YTD Price Performance: 13.62%
Average Trading Volume: 40,735
Technical Sentiment Signal: Sell
Current Market Cap: $321.9M